Ann: Voluntary Suspension Extension, page-36

Agree, very doubtful the ASX is questioning the Independent Report as they don't have the right to do this, they are pretty much toothless (fast to hand out speed ticket but never ask why a stock has dropped significantly) and that's were IP valuation is very important factor for a biotech startup entering commercialisation in determining the "true" valuation depending on potential market and there is no arguing this is massive for ResAppDx let alone a possible COVID-19 screening device. I think they are just renegotiation of the T/O bid......there was no way 11.5c would have been successful but like all business always do a low ball offer first.